Nutraveris

Archives

Tuesday, May 30, 2017
Category : News, Formation | Author : experts | Comment : No Comments
Tags:

Le baromètre des compléments alimentaires 2017: une Journée d’étude le 20 juin 2017 à Paris où un des intervenants est un expert de Nutraveris. Ce séminaire permet de :

  • Mettre à jour vos données de marché France & Europe.
  • Comprendre les évolutions d’usage, attitude et attentes des consommateurs.
  • Identifier les opportunités en termes de segment thérapeutique et typologie consommateurs.

 

Visualisez le programme 

 

A qui s’adresse cette journée:

Aux services Marketing, Communication, R&D, Export, des marques et fournisseurs des Industries de la santé.

 

Délivrable

A l’issue de la journée, il sera remis à chaque participant sur support numérique l’intégralité des slides de la présentation. Les résultats seront présentés sous forme de mapping, graphes, synthèse et recommandations.

 

Outils

  • Etude quantitative Baromètre 300 consommateurs 2017.
    • 50.000 données exploitées en quantitatif.
    • 70 questions de comportement posées sur 15 sphères thérapeutiques.
    • 70 Marques et 150 produits testés en spontané et assisté.
    • 115 ingrédients listés.
  • Etude qualitative, quantitative, consommateurs, distributeurs et prescripteurs sur 14 principales sphères thérapeutiques.
  • Etude des ventes et circuits de distribution sur 20 pays d’Europe.
  • Etudes et analyses règlementaires 28 pays.

 

Intervenants

EXPANSION CONSULTEAM : une équipe d’Experts en Etude consommateurs et Marketing Stratégique qui intervient depuis 15 ans sur les marchés de la santé et particulièrement complément alimentaire, en France et en Europe.

NUTRAVERIS : Cabinet de Conseil Scientifique/Réglementaire, leader en Europe sur le marché de la nutrition-santé.

 

Tarif,  incluant le déjeuner, les pauses et l’intégralité des slides de la conférence.

Client Expansion (achat d’un étude ad’hoc au cours des 12 derniers mois) : 650 € HT

Non client Expansion : 1.050 € HT

Possibilité de convention de formation. 

Inscription en ligne jusqu’au 16 Juin 2017 inclu en cliquant ici

( compléter le formulaire en ligne et de renvoyer le règlement TTC (ou la preuve du virement) à l’ordre d’Expansion Consulteam à contact@expansion-consulteam.com)

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

 

Sesame is rich in polyunsaturated fatty acids, fibre, phytosterol and lignans, which may all contribute to reduce blood pressure. The aim of this meta-analysis was to compile controlled trials assessing the effects of sesame consumption on blood pressure.

 

Sesame

 

8 controlled trials with a total of 843 participants met the eligibility criteria.

Results showed that sesame consumption can reduce systolic blood pressure (-7.83 mmHg, 95% CI: -14.12, -1.54, p < 0.05) and diastolic blood pressure (-5.83 mmHg, 95% CI: -9.58, -2.08, p < 0.01). By taking into account only studies with the highest methodology quality (4 trials), the authors highlighted a significant reduction in systolic blood pressure (-3.23 mmHg, 95% CI: -5.67, -0.79), but not in diastolic blood pressure (-2.08 mmHg, 95% CI: -4.85, 0.69).

 

In conclusion, sesame consumption can reduce systolic and diastolic blood pressure, leading to a possible reduction in the risk of cardiovascular diseases.

 

Khosravi-Boroujeni H, Nikbakht E, Natanelov E, Khalesi S. Can sesame consumption improve blood pressure? A systematic review and meta-analysis of controlled trials. J Sci Food Agric. 2017 Apr 7.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Friday, May 26, 2017
Category : News, INGREDIENTS, INNOVATION, CLINICAL EVIDENCE | Author : experts | Comment : No Comments
Tags:

NOL, Nutraveris Online, the most efficient data solution to create, keep up-to-date and launch your products in the 28 EU member states, used for 10years by more than 500 industry leaders informs you:

This randomised, double-blind, placebo-controlled parallel trial aims to assess whether supplementation with the probiotic Lactobacillus rhamnosus HN001 can reduce the prevalence of gestational diabetes mellitus (GDM). Pregnant women with a personal or partner history of atopic disease received 6×109 CFU of L. rhamnosus (n=212) or placebo (n=211) daily.

 Lactobacillus rhamnosus HN001 associations with gestational diabetes mellitus (GDM)

Lactobacillus rhamnosus HN001 associations with gestational diabetes mellitus (GDM)

There was a trend towards lower relative rates (RR) of GDM in the L. rhamnosus group, 0.59 (95% CI 0.32, 1.08; p=0.08).

L. rhamnosus was associated with lower rates of GDM in women aged ≥35 years (RR 0.31; 95% CI 0.12, 0.81, p=0.009)(a) and women with a history of GDM (p=0.004) (c).

GDM prevalence was significantly lower in the L. rhamnosus group, 2.1% (95% CI 0.6, 5.2), v. 6.5% (95% CI 3.5, 10.9) in the placebo group (p=0.03).

Lactobacillus rhamnosus supplementation from 14 to 16 weeks’ gestation may reduce gestational diabetes mellitus prevalence, particularly among older women and those with previous gestational diabetes mellitus.

 

Wickens KL, Barthow CA, Murphy R, Abels PR, Maude RM, Stone PR, Mitchell EA, Stanley TV, Purdie GL, Kang JM, Hood FE, Rowden JL, Barnes PK, Fitzharris PF, Crane J. Early pregnancy probiotic supplementation with Lactobacillus rhamnosus HN001 may reduce the prevalence of gestational diabetes mellitus: a randomised controlled trial. Br J Nutr. 2017 Apr 3:1-10.

 

This information has been sourced by NOL, a collaborative and complete tool which contains all Regulatory, Scientific and Marketing data

  • It solves all regulatory issues since it contains the required information on all ingredients authorized in the 28 European member states…on regulatory status, health claims, authority opinions
  • It protects your investments since it is updated in real time with reliable quality information analyzed and reviewed by our experts, available hotline.
  • It enables you to be the most responsive with monthly reports and live alerts and a personal use of the information with a report editing tool and customizable bookmarks.

With NOL let’s : 

  • Formulate new innovative products
  • Check if your already existing formulas are still compliant with the in force regulations
  • Adapt your existing formulas to the requirements of other European countries where you are willing to export them
  • Do scientific & regulatory & marketing monitoring which enable to anticipate the withdrawal of products, the safety issues, new interesting scientific studies, the arrival of new players on the market…

 

More information on www.nutraveris.com

Contact our Scientific & Regulatory experts at NUTRAVERIS

contact@nutraveris.com, +33 2 96 76 54 87

Wednesday, May 24, 2017
Category : News | Author : experts | Comment : No Comments
Tags:

For the third edition of NutraIngredients Awards – rewarded true innovation and cutting edge research in health foods, supplements and nutrition, NutraIngredients has appointed a diverse panel of experts to judge the 2017 Awards,  as Cédric Bourges CEO of  Nutraveris.

For 2017 edition, there were 13 prestigious award categories:

The awards ceremony took place on Wednesday 10th May at the 5* Starling Hotel, Geneva, after second day of Vitafoods Europe, and winners have been announced.

The full list of winners per category is available here.

Tuesday, May 23, 2017
Category : News | Author : experts | Comment : No Comments
Tags:

According to Dr Le Bloch, scientific project manager in health and nutrition at Nutraveris, Contract Research Organisations (CROs)  have increased the quality of their studies.

The need for robust research to validate health claims for a food ingredient has never been in doubt, but with regulations becoming ever more stringent the role of CROs appears to be changing...read the NutraIngredients article here

Nutraveris' booth at Vitafoods 2017

Nutraveris’ booth at Vitafoods 2017

The view at Vitafoods suggested CROs’ role was transitioning towards a  role  that was setting the research agenda.